Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Cauli

Showing results (141-150 of 180) with videos related to

Pageof 18
Sort By:
Rheumatology (Oxford, England)|May 7, 2021
Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA RegistryJurgen Sota, Donato Rigante, Rolando Cimaz, et al.
The Journal of Rheumatology|June 17, 2018
Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA StudyAlberto Cauli, Dafna D Gladman, Alessandro Mathieu, et al.
Rheumatology (Oxford, England)|January 8, 2025
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohortEliane Roth, Cosimo Bruni, Liubov Petelytska, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Rheumatology (Oxford, England)|August 4, 2025
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinibGiuseppe Lopalco, Eleonora Celletti, Maria Morrone, et al.
Clinical and Experimental Rheumatology|August 31, 2023
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDsLaura Scagnellato, Antonio Collesei, Andrea Doria, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Annals of the Rheumatic Diseases|March 18, 2019
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patientsFrances Humby, Myles Lewis, Nandhini Ramamoorthi, et al.
Joint Bone Spine|August 7, 2020
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEAFlorenzo Iannone, Ennio G Favalli, Roberto Caporali, et al.
Journal of Clinical Medicine|July 27, 2022
Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational StudySalvatore D'Angelo, Enrico Tirri, Angela Maria Giardino, et al.
Pageof 18

Showing results (141-150 of 180) with videos related to

Sort By:
Pageof 18
Rheumatology (Oxford, England)|May 7, 2021
Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA RegistryJurgen Sota, Donato Rigante, Rolando Cimaz, et al.
The Journal of Rheumatology|June 17, 2018
Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA StudyAlberto Cauli, Dafna D Gladman, Alessandro Mathieu, et al.
Rheumatology (Oxford, England)|January 8, 2025
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohortEliane Roth, Cosimo Bruni, Liubov Petelytska, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Rheumatology (Oxford, England)|August 4, 2025
Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinibGiuseppe Lopalco, Eleonora Celletti, Maria Morrone, et al.
Clinical and Experimental Rheumatology|August 31, 2023
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDsLaura Scagnellato, Antonio Collesei, Andrea Doria, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Annals of the Rheumatic Diseases|March 18, 2019
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patientsFrances Humby, Myles Lewis, Nandhini Ramamoorthi, et al.
Joint Bone Spine|August 7, 2020
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEAFlorenzo Iannone, Ennio G Favalli, Roberto Caporali, et al.
Journal of Clinical Medicine|July 27, 2022
Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational StudySalvatore D'Angelo, Enrico Tirri, Angela Maria Giardino, et al.
Pageof 18